EHA 2026 | Ponatinib consolidation may improve second treatment-free remission in CML
Gonzalo Carreño Gómez-Tarragona, MD, PhD, 12 de Octubre University Hospital, Madrid, Spain, presents updated findings from the ResToP trial (NCT04160546), showing that ponatinib consolidation before a second treatment-free remission attempt may improve the likelihood of maintaining molecular response after discontinuation in patients with chronic myeloid leukemia (CML). This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the main goals of CML treatment is achieving treatment-free remission. And we know that around only 50% of patients are going to achieve that in a first attempt and around 30% in a second attempt. So what we do with the RESTOP trial that was sponsored by the Spanish email group was doing a consolidation with ponatinib for two years to patients that had a failed first TFR attempt and what we saw is that after those two years of consolidation the TFR rates after one year of follow-up were really high...
One of the main goals of CML treatment is achieving treatment-free remission. And we know that around only 50% of patients are going to achieve that in a first attempt and around 30% in a second attempt. So what we do with the RESTOP trial that was sponsored by the Spanish email group was doing a consolidation with ponatinib for two years to patients that had a failed first TFR attempt and what we saw is that after those two years of consolidation the TFR rates after one year of follow-up were really high. 72% of patients were in MMR and 68% on TFR. So that means that treating patients or consolidating patients with more powerful TKIs before discontinuation might be helpful to improve those rates.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
